| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Fezile Ozdemir, Merve Demirbugen Oz, Kenan Can Tok, Emrah Dural, Yagmur Kır, Mehmet Gumustas, Bora Baskak, H Sinan Suze. The effects of UGT1A4 and ABCB1 polymorphisms on clozapine and N- desmethyl clozapine plasma levels in Turkish schizophrenia patients. Toxicology and applied pharmacology. vol 495. 2025-01-09. PMID:39761923. |
the effects of ugt1a4 and abcb1 polymorphisms on clozapine and n- desmethyl clozapine plasma levels in turkish schizophrenia patients. |
2025-01-09 |
2025-01-13 |
Not clear |
| Fezile Ozdemir, Merve Demirbugen Oz, Kenan Can Tok, Emrah Dural, Yagmur Kır, Mehmet Gumustas, Bora Baskak, H Sinan Suze. The effects of UGT1A4 and ABCB1 polymorphisms on clozapine and N- desmethyl clozapine plasma levels in Turkish schizophrenia patients. Toxicology and applied pharmacology. vol 495. 2025-01-09. PMID:39761923. |
clozapine (clz) is an antipsychotic which is particularly used in treatment resistant schizophrenia patients who do not respond to other agents. |
2025-01-09 |
2025-01-13 |
Not clear |
| Fezile Ozdemir, Merve Demirbugen Oz, Kenan Can Tok, Emrah Dural, Yagmur Kır, Mehmet Gumustas, Bora Baskak, H Sinan Suze. The effects of UGT1A4 and ABCB1 polymorphisms on clozapine and N- desmethyl clozapine plasma levels in Turkish schizophrenia patients. Toxicology and applied pharmacology. vol 495. 2025-01-09. PMID:39761923. |
the aim of the study is to evaluate the effects of abcb1 rs1045642 and ugt1a4 rs2011425 polymorphisms on clz and its major metabolite n- desmethly clozapine (dclz) plasma concentrations in patients with schizophrenia. |
2025-01-09 |
2025-01-13 |
Not clear |
| Abdul Qadir, Syed Umer Jan, Muhammad Harris Shoaib, Muhammad Sikandar, Rabia Ismail Yousuf, Fatima Ramzan Ali, Fahad Siddiqui, Abdul Jabbar Magsi, Ghulam Mustafa, Muhammad Talha Saleem, Shafi Mohammad, Mohammad Younis, Muhammad Arsala. Formulation development and evaluation, in silico PBPK modeling and in vivo pharmacodynamic studies of clozapine matrix type transdermal patches. Scientific reports. vol 15. issue 1. 2025-01-08. PMID:39774012. |
clozapine is a potent serotonin receptor antagonist and commonly used for the treatment of schizophrenia. |
2025-01-08 |
2025-01-13 |
Not clear |
| Shanathan Sritharan, Kindelan Murray, Dominic Lam, Daniel Wittaker, Aaron Sverdlov, Andrew Boyle, Allan Davies, Trent Williams, Nicholas Collin. A retrospective analysis of cardiovascular outcomes of clozapine treated individuals within Hunter New England. Internal medicine journal. 2025-01-08. PMID:39776141. |
clozapine has demonstrated superiority in improving both positive and negative symptoms of treatment-resistant schizophrenia; however, there are associated treatment-limiting side effects, including myocarditis, cardiomyopathy and agranulocytosis. |
2025-01-08 |
2025-01-13 |
Not clear |
| Ying Zhang, Ranli Li, Ximing Chen, Yachen Li, Qiuyu Zhang, Lei Yang, Lina Wang, Yun Sun, Fuqiang Mao, Chuan Jun Zhu. Clozapine Induces Agranulocytosis via Inflammatory and Hematopoietic Cytokine Induction of the JAK-STAT Signaling Pathway: Evidence From Network Pharmacology and Molecular Docking. CNS neuroscience & therapeutics. vol 31. issue 1. 2025-01-08. PMID:39776289. |
clozapine exhibits significant therapeutic efficacy in schizophrenia, especially treatment-resistant schizophrenia. |
2025-01-08 |
2025-01-13 |
Not clear |
| Ximing Chen, Chuanjun Zhuo, Lei Yang, Qiuyu Zhang, Li Cha. Network pharmacology and molecular docking to explore mechanisms of clozapine-induced cardiac arrest. Journal of psychiatry & neuroscience : JPN. vol 50. issue 1. 2025-01-03. PMID:39753306. |
clozapine is superior to all other antipsychotics in treating schizophrenia in terms of its curative efficacy; however, this drug is prescribed only as a last resort in the treatment of schizophrenia, given its potential to induce cardiac arrest. |
2025-01-03 |
2025-01-06 |
Not clear |
| M M Koopmans, A B Koopmans, E van Beijeren, F M E Co. [A case of clozapine-induced myoclonic epilepsy]. Tijdschrift voor psychiatrie. vol 66. issue 10. 2025-01-03. PMID:39749598. |
clozapine is effective in treatment-resistant schizophrenia. |
2025-01-03 |
2025-01-05 |
Not clear |
| Rajkumar Sanahan, Vanteemar S Sreeraj, Satish Suhas, Vijay Kumar, Jagadisha Thirthalli, Ganesan Venkatasubramania. Response to clozapine and its predictors in treatment-resistant schizophrenia spectrum disorders: A retrospective chart review. Schizophrenia research. vol 275. 2024-12-31. PMID:39740316. |
a total of 54 % responded to clozapine, with much or very much improvement in positive and overall symptoms of schizophrenia by the end of 12 weeks of clozapine initiation. |
2024-12-31 |
2025-01-03 |
Not clear |
| Duilin Liu, Caiyun Zhu, Hui We. Clozapine and rapamycin reverse behavioral abnormalities in an animal model of autoimmune schizophrenia. Neuropharmacology. 2024-12-29. PMID:39733937. |
clozapine and rapamycin reverse behavioral abnormalities in an animal model of autoimmune schizophrenia. |
2024-12-29 |
2025-01-01 |
Not clear |
| Gamze Gürcan, Berk Atalay, Ece Devec. Clozapine-Associated Sialorrhea: A Literature Review. Journal of clinical psychopharmacology. 2024-12-26. PMID:39724598. |
clozapine has demonstrated efficacy in treating treatment-resistant schizophrenia; however, it has a wide range of side effects. |
2024-12-26 |
2024-12-29 |
Not clear |
| Ismael Olmos, Carina Ricciardi, Mauricio Mato, Natalia Guevara, Sabrina Acuña, Cecilia Maldonado, Marta Vázquez, Mauricio Toledo, Clara Menéndez, Valentina Blanco, José L Badano, Alfonso Cayota, Lucia Spangenberg, Magdalena Cardenas-Rodrigue. Optimization of Clozapine Treatment: Study of Variables Affecting Response in Uruguayan Patients With Schizophrenia. Journal of clinical psychopharmacology. vol 45. issue 1. 2024-12-23. PMID:39714785. |
optimization of clozapine treatment: study of variables affecting response in uruguayan patients with schizophrenia. |
2024-12-23 |
2024-12-25 |
Not clear |
| Ismael Olmos, Carina Ricciardi, Mauricio Mato, Natalia Guevara, Sabrina Acuña, Cecilia Maldonado, Marta Vázquez, Mauricio Toledo, Clara Menéndez, Valentina Blanco, José L Badano, Alfonso Cayota, Lucia Spangenberg, Magdalena Cardenas-Rodrigue. Optimization of Clozapine Treatment: Study of Variables Affecting Response in Uruguayan Patients With Schizophrenia. Journal of clinical psychopharmacology. vol 45. issue 1. 2024-12-23. PMID:39714785. |
clozapine is the recommended drug for treatment-resistant schizophrenia. |
2024-12-23 |
2024-12-25 |
Not clear |
| Ismael Olmos, Carina Ricciardi, Mauricio Mato, Natalia Guevara, Sabrina Acuña, Cecilia Maldonado, Marta Vázquez, Mauricio Toledo, Clara Menéndez, Valentina Blanco, José L Badano, Alfonso Cayota, Lucia Spangenberg, Magdalena Cardenas-Rodrigue. Optimization of Clozapine Treatment: Study of Variables Affecting Response in Uruguayan Patients With Schizophrenia. Journal of clinical psychopharmacology. vol 45. issue 1. 2024-12-23. PMID:39714785. |
this study evaluated genetic and nongenetic variables that may affect clozapine plasma concentrations in uruguayan patients with schizophrenia. |
2024-12-23 |
2024-12-25 |
Not clear |
| Junyu Sun, Fernando Zelaya, Kyra-Verena Sendt, Grant McQueen, Amy L Gillespie, John Lally, Oliver D Howes, Gareth J Barker, Philip McGuire, James H MacCabe, Alice Egerto. Response to clozapine in treatment resistant schizophrenia is related to alterations in regional cerebral blood flow. Schizophrenia (Heidelberg, Germany). vol 10. issue 1. 2024-12-23. PMID:39715777. |
response to clozapine in treatment resistant schizophrenia is related to alterations in regional cerebral blood flow. |
2024-12-23 |
2024-12-26 |
human |
| Junyu Sun, Fernando Zelaya, Kyra-Verena Sendt, Grant McQueen, Amy L Gillespie, John Lally, Oliver D Howes, Gareth J Barker, Philip McGuire, James H MacCabe, Alice Egerto. Response to clozapine in treatment resistant schizophrenia is related to alterations in regional cerebral blood flow. Schizophrenia (Heidelberg, Germany). vol 10. issue 1. 2024-12-23. PMID:39715777. |
pet and spect studies in treatment-resistant schizophrenia (trs) have revealed significant alterations in regional cerebral blood flow (cbf) during clozapine treatment, which may vary according to the clinical response. |
2024-12-23 |
2024-12-26 |
human |
| Junyu Sun, Fernando Zelaya, Kyra-Verena Sendt, Grant McQueen, Amy L Gillespie, John Lally, Oliver D Howes, Gareth J Barker, Philip McGuire, James H MacCabe, Alice Egerto. Response to clozapine in treatment resistant schizophrenia is related to alterations in regional cerebral blood flow. Schizophrenia (Heidelberg, Germany). vol 10. issue 1. 2024-12-23. PMID:39715777. |
we then compared cbf in the trs group, before and after 12 weeks of treatment with clozapine (n = 24); and examined the relationship of those differences against changes in positive and negative syndrome scale for schizophrenia (panss) scores over the treatment period. |
2024-12-23 |
2024-12-26 |
human |
| Chanunnat Kitsinthopchai, Siripun Kumpeera, Apiradee Sangngarm, Tuanthon Boonlu. Prevalence and Factors Associated with Hypersalivation in Schizophrenia Inpatients Treated with Clozapine: A Retrospective Study. Hospital pharmacy. 2024-12-20. PMID:39703771. |
prevalence and factors associated with hypersalivation in schizophrenia inpatients treated with clozapine: a retrospective study. |
2024-12-20 |
2024-12-22 |
Not clear |
| Laura McMahon, Maddison Giudice, Elias Wagner, Alkomiet Hasan, Matthew K Burrage, John Amerena, Cooper Fox, Karl Winckel, Timothy Tanzer, Lesley Smith, Nicola Warren, Dan Siskind, Nicole Korma. Clozapine rechallenge following myocarditis: a systematic review of rechallenge cases. CNS spectrums. 2024-12-20. PMID:39703983. |
clozapine is the antipsychotic medication with the greatest efficacy in treatment-resistant schizophrenia (trs). |
2024-12-20 |
2024-12-22 |
Not clear |
| Natalia Daher, Mateus Diniz, Renan Biokino, Pedro Lorencetti, Carolina Ziebold, Raffael Massuda, Ary Gadelh. Hematological Changes in Clozapine Users: A Study in a Brazilian Community Sample. Trends in psychiatry and psychotherapy. 2024-12-20. PMID:39705153. |
clozapine is the only antipsychotic with proven superior efficacy for treatment-resistant schizophrenia. |
2024-12-20 |
2024-12-23 |
Not clear |